Calliditas patents expiration

1. Tarpeyo patents expiration

TARPEYO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491932 CALLIDITAS Compositions for the oral delivery of corticosteroids
May, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-389) Dec 15, 2028
Orphan Drug Exclusivity(ODE-464) Dec 20, 2030
New Product(NP) Dec 15, 2024

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 15 December, 2021

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression


More Information on Dosage

TARPEYO family patents

Family Patents